Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $0.85
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on Singular Genomics Systems (NASDAQ:OMIC) but has reduced the price target from $0.95 to $0.85.
January 23, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Singular Genomics Systems but lowered the price target from $0.95 to $0.85.
The reduction in price target by Goldman Sachs, a major financial institution, suggests a less optimistic valuation of Singular Genomics Systems, which could lead to a negative short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100